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Abstract
THE INC IDENCE OF POSTOPE R AT I VE RETCH ING A ND VOM ITING IN THE ADULT
PAT IENT UNDERGO ING ABDO M INAL SU RGE RY FOLLOWING INTRAOPE RAT IVE
ADM I NISTR ATION OF D ROPE R IDOL
Gary L. Miller, B.S. N.

The com plication of postoperative nausea and vomiting is still one
of the most common today.

The potential for secondary complications

associated with retching and vomiting such as aspiration pneumonitis
strain of suture line with possible hemorrha ge, and potential fluid and
electrolyte imbalance makes prevention of retching and vomiting a
primary concern in the management of the postoperative patient.
The use of antiemetic drugs to prevent or control postoperative
nausea and vomiting is a long-standing practice.

Droperidol, an

antiemetic, routinely used since being introduced in 1963, has been
found to be successful in treating postoperative nausea and vomiting.
This study examines the effect of droperidol .018 mg/kg given
intramuscularly one half hour prior to the end of anesthesia on
postoperative emesis in the adult gynecological patient presenting for
total abdominal hysterectomy.
Twelve patients were in this double-blind study, six acted as
controls and six were in the experimental group.

All subjects were

premedicated with morphine sulfate 0 .1 mg/kg and glycopycolate 0.2 mg,
intramuscularly administered.

All were induced with pentathol 4 mg/kg

preceded by curare 3 mg and followed by succinylcholine 1 .5 mg/kg for
intubation.

The subjects were maintained on isoflurane, sixty percent

nitrous in oxygen, and pancuronium for relaxation.
of similar age and weight.

The subjects were

Duration of anesthesia was similar with a

mean of 2.93 hours overall.
The incidence of retching or vomiting was considered as the same
result.

The droperidol group had one subject retch only and another

retch and vomit.

This gave a 33 percent incidence of retching and

vomiting. T he control group had three subjects retch and vo mit, giving
a 50 percent incidence.

The small sample size provided no statistical

significance.
The results showed a trend of decreased vomiting in the adult
subject presenting for total abdominal hysterectomy.

The routine use

of droperidol in this particular population cannot be recommended from
these results.

CHAPTE R 1
Introduction

Problem Statement
The complication of postoperative nausea and vomiting is still one
of the most common today ( 1,2,3).

Patients often reveal that fear of

postoperative nausea and vomiting is one of their primary concerns.

A

prior experience with postoperative nausea and vomiting may increase
that patient's stress level and make it much more difficult to
emotionally prepare that patient for surgery.

The potential for

secondary complications associated with retching and vomiting such as
aspiration pneumonitis, strain of suture line with possible hemorrhage,
cerebral accident due to increased intracranial pressure, potential
fluid and electrolyte imbalance, and possible trauma to the esophagus,
makes prevention of retching and vomiting a primary concern in the
management of the postoperative patient.
The use of antiemetic drugs to prevent or control postoperative
nausea and vomiting is a long standing-practice dating back to the
1950's.

Droperidol, an antiemetic, routinely used since being

introduced in 1963 has been found to be successful in treating
postoperative nausea and vomiting (2,4,5,6,7,8).

Droperidol acts by

blocking the dopaminergic receptors in the Chemoreceptor Trigger Zone
(CTZ).

This inhibits the transmission of emetic stimuli from the CTZ

to the Emesis Center (EC).

The EC actually stimulates vomiting.

effectiveness of Droperidol has been often studied but very little

1

The

2
research is based on a milligram per kilogram basis.
The purpose of this study is to arrive at the effectiveness of
Droperidol in preventing postoperative retching and vomiting based on a
specific milligram per kilogram basis.
Research Question
What is the effect of intramuscular droperidol given
intraoperatively 30 minutes prior to the end of anesthesia on the
incidence of postoperative retching and vomiting in the adult patient
undergoing intra-abdominal surgery without bowel resection, for 24
hours postop?

Definition of Terms
1.

Retching:

The active attempt of the patient to expel stomach
contents without success.

2.

Vomiting:

The active effort of the patient to expel stomach
contents with success.

3.

Droperidol (Inapsine):

A butyrophenone tranquilizer with

alpha adrenergic and dopaminergic antagonistic
qualities causing moderate hypotension, sedation,
and antiemetic effects.
4.

Adult patient:

A non-obese, ASA I or II female, 18-49 years

of age undergoing an intra-abdominal surgical
procedure without bowel resection .
5.

ASA:

American Society of Anesthesiologists.

A categorizing

of patient's physical condition.
A)

Class I:

"The patient has no organic, physiologic,

biochemical, or psychiatric disturbance.

The

3
pathologic process for which the operation is to be
performed is localized and does not entail a
systemic disturbance ."
B)

"Mild to moderate systemic disturbance

Class II:

caused either by the condition to be treated
surgically or by other pathophysiologic processes. "
6.

End of Anesthesia:

7.

Intramuscular:

B.

Non-obese:

Removal of the endotracheal tube.

Left deltoid injection.

Less than 20 percent above ideal body weight .

Hypothesis
The adult patient will experience no reduction in the incidence
of postoperative retching and/or vomiting after receiving droperidol
.01B mg/kg 1M intra-operatively .

Variables
Dependent:
Independent:

Postoperative retching and vomiting.
Intramuscular administration of droperidol .01B mg/kg

administered intra-operatively.

Assumptions
1.

The nursing staff will record all incidents of retching and

vomiting postoperatively.
2.

The patient will accurately report all incidents of retching

and vomiting not recorded by the nursing staff.

Limitations
1.

The investigator will rely on the nursing staff to accurately

record all incidents of retching and vomiting.
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2.

The investigator will rely on the skill of the anesthetist to

ventilate the patient without pushing air into the stomach.

Delimitations
1.

The patient will be assigned to one of two groups, a control

or an experimental group, based on a random table of numbers in a
double-blind fashion.
2.

In an effort to control the variables of postoperative

retching and vomiting within this study, a homogeneous group consisting
of females, ages 18-49 years, ASA I or I I, non-obese, undergoing an
intra-abdominal surgical procedure lasting two to four hours without
bowel resection were utilized .

Theoretical Framework
Nausea, Vomiting, and Associated Factors
Vomiting is described as the active expulsion of gastric contents
through the mouth.

This is immediately preceded by tachypnea,

salivation, and pupil dilation resulting from an autonomic discharge.
There are two areas of the brain responsible for vomiting, the emesis
center ( EC ) and the chemoreceptor trigger zone ( CTZ ) .

These two centers

are located in the medulla and when sufficiently stimulated, vomiting
occurs (9,10).
The EC is located near the dorsolateral border of the lateral
reticular formation and ventral to the tractus solitarious and its
nucleus.

This area of the medulla also contains the respiratory

center, salivatory nuclei, vasomotor center, vestibular nuclei, and
bulbofacilitatory and inhibitory systems .

The EC is located in the

center of these regulatory nuclei which explains the patterned
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response, earlier described, during vomiting ( 10).

The EC may be

directly stimulated by efferent pathways from various locations.

For

example, mucosal irritation of the gastrointestinal tract, mechanical
distention of bowel or biliary tract, myocardial infarction, meniere's
disease, vestibular neuronitis, or viral hepatitis may stimulate the EC .
The EC may also be indirectly stimulated via the CTZ (3).
The CTZ is located in the medulla superficial to the EC area
postrema in the floor of the fourth ventricle.

The CTZ can be

stimulated by drugs such as digitalis, antibiotics, cytotoxic agents,
alcohol, er gots, opiates, and inhalation anesthetics.

Also, the CTZ

may be stimulated by toxicosis such as diabetic acidosis, uremia, and
carcinomatosis, or stimulated by radiation and motion sickness (3, 1 1).
There are numerous factors that correlate with the incidence of
vomiting when considering the postoperative patient, i .e., sex, age,
weight, preoperative medication, anesthetic technique, operative site,
duration, postoperative pain, and gonadotropin levels (9,12, 13, 14)
Studies have shown that female patients experience an increased
incidence of vomiting as compared to male patients (9) .

Janhunen and

Tammisto reported an 18. 1 percent difference in the incidence of
postoperative vomiting between male and female patients ( 15).

A

difference of 15.8 percent was reported by Iwamoto and Schwartz (4).
The differe nce in the incidence of postoperative vomiting between the
sexes is also interrelated to the age of the patient.
Various age groups of adult patients experienced a difference in
the incidence of postoperative vomiting (6, 12, 14,16)

Females 40-49

years of age and males 60-69 years of age experienced the highest
incidence of postoperative vomiting compared to other age groups from
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20-29 through 60-69 years of age ( 15).
The obese patient, either male or female, experiences a higher
incidence of postoperative nausea and vomiting (6, 7, 12, 14).

Bellville

postulated that obese patients have a large fat reservoir to absorb the
anesthetics as well as other drugs which chemically stimulate nausea
and vomiting (9).
The pre-operative medication also plays a role in the incidence of
postoperative nausea and vomiting (7).

It is generally known that

narcotics are associated with an increased incidence of vomiting
postoperatively when used as a premedicant.

Morphine, with a 42

percent incidence of postoperative nausea and vomiting, has been the
most extensively studied, but meperidine has also been implicated in
postoperative nausea and vomiting ( 14).

Bellville found a biphasic

dose relationship curve when comparing incidence of postoperative
nausea and vomiting to the dose of meperidine administered .

The

incidence of nausea and vomiting was higher at doses lower than and
higher than one m illigram/kilogram (9).
The anesthetic technique has long been implicated in the incidence
of postoperative nausea and vomiting.

Bonica et al. ( 12) implicated

ether to have an incidence of 64.2 percent nausea and vomiting.
However, Bellville equated this high percentage with anesthetic depth
when ether was used for muscle relaxation and was obtained by deep
levels of anesthesia ( 17).

Bellville found the incidence of

postoperative nausea and vomiting with cyclopropane to be 26
percent (9).

Halothane was later studied and found to have a low

incidence of postoperative nausea and vomiting of 19. 5 percent ( 13).
Ethrane was studied for its contribution to postoperative nausea and
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vomiting by Iwamoto and Schwartz (4).

Results of 42. 1 percent

incidence of nausea and vomiting were obtained.

In another study,

nitrous oXide/oxygen/fentanyl anesthetic technique was compared to
isoflurane/fentanyl/oxygen and isoflurane/oxygen technique.

Of the

patients from each group that experienced nausea and vomiting,
6 1 percent received 70 percent nitrous oxide/oxygen/fentanyl,
30 percent received 1- 1.5 MAC isoflurane/oxygen/fentanyl, and
25 percent received 1-1.5 MAC isoflurane/oxygen ( 1).

Besides the

agent used, the skill of the anesthetist must be considered as part of
the anesthetic technique.

Improper ventilation can lead to air trapped

in the stomach, elevation of P C0 , decreased P0 , and hypotension,
2
2
all of which can lead to increased risk of vomiting (9, 17).
The operative site has been implicated in contributing to the
incidence of postoperative vomiting and retching.

Intra-abdominal

procedures resulted in a higher incidence compared to other operative
sites (2, 9, 14, 15, 17).

Mortensen et al. reported 6 1. 1 percent and

Bonica reported 44 .2 percent incidence of postoperative nausea
and vomiting following intra-abdominal procedures (6, 12).
The duration of anesthesia has been correlated with an increased
incidence of postoperative nausea and vomiting (2,4,7, 14).

However,

most studies used short cases lasting less than 15 minutes to 2 hours.
Bellville studied a greater range divided into one hour blocks and found
a significant difference ( 17).

He found only 17.5 percent incidence

with cases 1/2 hour to 1 1/2 hours, 28.4 percent with 1 1/2 hours to
2 1/2 hours, and 46 percent incidence with 2 1/2 to 3 1/2 hours .
Postoperative pain and its treatment play a role in the incidence
of postoperative nausea and vomiting.

Bellville (9) found that 4 1

8
percent of those that had emesis experienced pain .

While it is

difficult to evaluate postoperative analgesics for pain and their
significance towards nausea and vomiting, narcotics have already been
implicated concerning nausea and vomiting, and one can assume a
contri bution from them.

Attempts to determine a significance proved

unsuccessful (15).
The level of gonadotropin associated with the third and fourth
week of the menstrual cycle has been implicated in an increased
incidence of postoperative nausea and vomiting (9,14,15) .

Bellville

goes on to say that there is a definitive correlation between the
greatest incidence of nausea and vomiting, and the gonadotropin levels
peaking between the sixth through the twelfth week of pregnancy.
However, no difference in postoperative nausea and vomiting exist
between premenopausal and postmenopausal women (17).

Droperidol
Droperidol is a butyrophenone tranquilizer and neuroleptic agent.
It was first synthesized in Belgium by Janssen.

In the original

studies, Janssen discovered that droperidol had a potent antiemetic
effect (18).
While droperidol's original anesthetic use as a premedicant,
induction agent, or use with fentanyl as a neuroleptanesthetic
continued, more studies appeared a bout it's superior antiemetic effects
(2,3,4, 5,6, 7, 8).

This effect is caused by droperidol blocking

dopaminergic receptors in the chemoreceptor trigger zone (CTZ).

This

antagonist activity inhibits the transmission of emetic stimuli from
the CTZ to the emesis center (EC) (19,20,21).

Loeser et al. suggests

that droperidol may also have a direct effect on the EC itself (5).
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Droperidol has also demonstrated alpha blocking ability resulting in
moderate decrease in blood pressure after administration of moderate
doses of 5 mg or greater in adults

(20,22).

Droperidol was found to be effective as an antiemetic
after intramuscular administration and last up to
peak effect

6

to

12

The metabolism of droperidol is very rapid.

similar response between patients.
make up

86

134

drug had been excreted

(19).

hours with its

The elimination

minutes,

suggesting a

The metabolites are inactive and

percent of the excreted product.

up 75 percent of the products

minutes

(2).

hours post administration

half-life in human subjects was uniformly

24

30

After

Urinary excretion makes

24

hours,

83

percent of the

(21).
Conclusion

Nursing goals of caring for the postoperative patient suffering
from nausea and vomiting are to maintain proper hygiene, maintain fluid
and electrolyte ba�ance, achieve rest, prevent physical injury, achieve
comfort,

and prevent psychological alteration.

The physician's goal is to stop emesis by prescribing the
antiemetic that is currently the most effective drug available.
The interrelationship that the medical discipline and the nursing
diSCipline have is a co-existing responsibility to therapeutically
intervene and correct the postoperative complication.

CHAPTER 2
Literature Review

In the 1950's Borison and Wang contributed immensely to our
understanding of the mechanism of nausea and vomiting.

Through

research with cats using implanted electrodes they were able to locate
two separate areas in the medulla responsible for vomiting (23).

The

incidence of postoperative nausea and vomiting was quite high at this
time and was generally attributed to ether, the primary anesthetic of
that time ( 12).

Research of preventing postoperative nausea and

vomiting was primarily focused on antihistamines and anticholinergics.
The list of variables associated with postoperative nausea and vomiting
was growing.

Bellville et al. published an article outlining a

research format to control these variables and to accurately compare
the many antiemetics entering the market (24).

Variations on this

format are still used today for research of antiemetics.
In the early 1960's, phenothiazines were considered the drug of
choice for postoperative nausea and vomiting (9).

Then Janssen et al

( 18) introduced a butyrophenone called droperidol with potent
antiemetic effects.

Research was also continuing to define the anatomy

involved in the process of vomiting ( 10).

By 1969, halothane was well

established as an anesthetic and studies revealed it to have a reduced
incidence of postoperative nausea and vomiting when compared to ether
and cyclopropane.

Gold reported a 14.3 percent incidence of

postoperative nausea and vomiting associated with halothane ( 13).

10

That
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same study resulted in 5 1. 8 percent with ether and 43.6 percent with
cycloprane.

Gold's study utilized 1223 women under going gynecological

surgery.
By 1970, the list o f variables associated with postoperative
nausea and vomiting was nearly complete.
and published the following list:

McKie reviewed the literature

anesthetic agents and technique,

premedicant drugs, operative site, age and sex, duration of operation,
hypoxia, hypercarbia and hypotension, rough handling of the patient,
experience of the anesthetist, physical status, use of nasogastric
tube, position, emotional factors, and postoperative pain ( 14).
Janhunen and Tammisto further supported McKie's findings ( 15).

Later

Cressman et al. and Soudijn et al., in separate studies, contributed to
the understanding of the absorption, metabolism, excretion, and
mechanism of action of droperidol in human subjects ( 19,2 1).

This

lead to an increase in the studies of droperidol as an antiemetic agent.
Patton et al. compared it in a double blind study using droperidol and a
placebo (7).

Hi� study, utilized 4 1 patients undergoing hysterectomy

with ether anesthesia and revealed a 56 percent difference in the
incidence of postoperative nausea and vomiting during the first six
hours.

Winning et al. compared droperidol to diphenido1 and a placebo

in 2 1 patients and found that droperidol resulted in a 14 percent
difference in the incidence of postoperative nausea and vomiting
compared to diphenidol and a 22 percent difference compared to the
placebo (8).

Iwamoto and Schwartz studied the effects of droperidol on

78 ophthalmic surgery patients using enflurane as the anesthetic (4).
The placebo group experienced an incidence of 42 percent postoperative
nausea and vomiting.

The patients who received droperidol experienced
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an incidence of 16 percent postoperative nausea and vomiting.
Korttila et al. compared domperidone, droperidol, and metaclopramide in
the prevention and treatment of nausea and vomiting following balanced
general anesthesia (2).

Korttila used a lower dose of droperidol than

usually studied, 1. 25 milligrams.

Once again, droperidol provided the

lowest incidence, 17 percent, of postoperative nausea and vomiting
compared to the placebo, 40 percent; metaclopramide and domperidone, 35
and 40 percent, respectively in the 185 females undergoing orthopedic
surgery.

A similar comparison of droperidol, haloperidol and

prochlorperazine proved that droperidol was the superior antiemetic (5).
Droperidol has also been studied for characteristics other than
antiemetic effects.

For example, Soroker et al. compared diazepam and

droperidol for their effects on respiratory function.

Diazepam

10 milligrams didn't effect respiratory function, but droperidol
5 milligrams reduced the tidal volume in all 14 normal subjects.
However, the reduction of 13. 3 percent was not enough to alter blood
gas tensions (25).
The 1980's have brought more research on the variables implicated
in postoperative nausea and vomiting and more research on the potent
antiemetic, droperidol.

Perreault et al. studied variations in middle

ear pressure during nitrous oxide administration and found, in patients
with blocked eustachian tubes, that negative pressure in the immediate
postoperative period was sufficient to cause irritation of the
vestibular system leading to nausea and vomiting (26).

Another study

of 77 females found a 6 1 percent incidence of postoperative nausea and
vomiting associated with 70 percent nitrous oxide ( 1) .

Mortensen

studied the antiemetic effects of droperidol on 300 gynecological

13
patients using nitrous oxide 67 percent in oxygen and pancuronium.
different doses were used as well as a placebo .

Two

Mortensen found

34. 4 percent incidence postoperative nausea and vomiting in the placebo
group and in the 2.5 and 5. 0 milligram groups, 15.2 and 10.3 percent
were respectively recorded (6).

Santos and Datta studied the effects

of droperidol on 50 subjects undergoing elective caesarean under spinal
anesthesia (27).

Their placebo group experienced 40 percent and their

droperidol group experienced 12 percent postoperative nausea and/or
vomiting.

Interestingly enough, the droperidol group experienced only

nausea 12 percent and the placebo group experienced 12 percent
vomiting.
This study will attempt to add to the body of knowledge on the
use of droperidol in adults.
Mortensen (6).

The research is similar to that of

The research is attempting to update the efficacy of

droperidol with today's anesthetics.

To date, no published research

exists utilizing isoflurane, quickly becoming the standard inhalation
anesthetic, and the concomitant use of droperidol as an antiemetic.

CHAPTE R 3
Methodology

Research Design
This investigator conformed to a quasi-experimental design.
were two groups that patients were randomly assigned to.

There

Patients in

group I received droperidol .018 mg/kg intramuscularly 30 minutes prior
to the end of anesthesia.

Group II received no antiemetic treatment

intra-operatively.
The subjects were a sample of convenience and were assigned to a
group based on random sampling from a table of random numbers.

Patient

numbers were assigned on the basis of the sequence that patients
consented to the study .

The selection of group assignment was double

blind.

Population, Sample, Setting
The population of this study consisted of the patients assigned to
the gynecological surgery service of a 1, 000 bed teaching hospital
located in the southeast United States.

A sample of convenience was

drawn from this population which met the criteria of this study.
subjects were female,

The

18-49 years of age, ASA class I or I I, nonobese,

and scheduled for intra-abdominal gynecological surgery under
endotracheal general anesthesia.
Protocol
The protocol and consent forms were approved by the Committee on
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the Conduct of Human Research.

The protocol was discussed with the

patient the night before surgery and informed consent was obtained.
Group I and I I patients were premedicated with morphine sulfate
.1 mg/kg and glycopycolate .2 mg intramuscularly.

All premedications

were given on call to the operating room.
A standard induction was used on both groups consisting of D-tubo
curare 3 milligrams, pre oxygenate with 100 percent oxygen for 5
minutes, pentathol 50 milligrams test dose followed by 4 mg/kg,
Succinylcholine 1 .5 mg/kg, laryngoscopy and endotracheal intubation.
Maintenance anesthesia was by isoflurane, nitrous oxide 60 percent
in o xygen, and muscle relaxation by pancuronium .04 mg/kg as needed.
Appropriate intravenous fluid administration and monitoring were
conducted.
Subjects were eliminated from the study if the pre-operative
medication was inadequate and the patient appeared emotionally
distraught.

Also, patients were eliminated if the induction resulted

in air in the stomach, hypoxia, hypercarbia, or hypotension greater
than 30 percent of baseline.

Furthermore, a range of two to four hours

for the entire procedure was established to make the duration
consistent.
Approximately 30 minutes before completion of anesthesia, group I
received droperidol . 018 mg/kg intramuscularly in the left deltoid
muscle.

Group I I received one half milliliter normal saline at that

same time in the same fashion.
Data collection of retching and vomiting over the next 24 hours
was accomplished by review of the anesthesia record, recovery room
record, and the floor nursing record.

The patient was also questioned
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as to the incidence of and frequency of retching and/or vomiting.
Nausea was not looked at by the investigator to eliminate the
subjective nature of collecting that data.

CHAPTE R 4
Analysis of Data

A total of 13 subjects were in this study.

One subject was

excluded from the data analysis due to failure to meet intraoperative
and postoperative criteria.

Subject number three had a nasogastric

tube placed intraoperatively secondary to the presence of air in the
stomach after induction.

This left a total of 12 subjects for data

analysis.
There were six control subjects in the study.

The mean age was 38

years (range 3 1 to 45 years), and the mean weight was 68.4 kilograms
(range 56 to 76.4 kilograms).
(range 2.5 to 3.2 hours).

The mean anesthesia time was 2.88 hours

Of the six control subjects, three

experienced retching and vomiting postoperatively.

Two out of the

three control subjects which experienced retching and vomiting
complained of postoperative pain and received morphine sulphate for
analgesia in the recovery room.
There were six subjects in the experimental group.

The mean age

was 37 years (range 28 to 46 years), and the mean weight was 54
kilograms (range 49 to 60 kilograms).
hours (range 2.7 to 3.4 hours).

Mean anesthesia time was 2.98

One out of the six experimental

subjects experienced retching and vomiting postoperatively.
out of six experienced only retching.

Also, one

The one experimental subject

that experienced postoperative retching and vomiting complained of
postoperative pain and received morphine sulphate for analgesia in the

17
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recovery room.
All 12 subjects received identical preoperative medications and
anesthetics .

All 12 subjects underwent total abdominal hysterectomies.

Of the six control subjects, three (50 percent) retched and/or vomited .
The six experimental subjects had two (33 percent) retch and/or vomit.
The small sample size of this study requiring a 2 x 2 table
dictated that the Fisher Exact Test (one tail) be utilized for
statistical analysis (29).

The results proved to be statistically

insignificant at the . 05 level and failed to reject the null
hypothesis.

Therefore, no difference in retching and/or vomiting

between control and experimental exists (Table 1).

Analysis of

subjects' weight and duration of anesthesia also proved to be
statistically insignificant based on the student's T test.

However,

the mean age of the subjects which retched and/or vomited compared to
those who did not was significant at the .05 level.

Further

scrutinizing this data with the Fisher Exact Test demonstrated that all
of the subjects 40 to 49 years of age experienced retching and/or
vomiting.

This age group represents four out of the five subjects that

experienced retching and/or vomiting (Table 2).

Analysis of subjects

who received postoperative morphine sulphate for complaints of pain
proved statistically insignificant on the .05 level .

Postoperative

drowsiness was reported more frequently in the subjects who received
droperidol.
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Table 1
Difference in Retching and/or Vomiting
in Control and Experimental
(P<.05)
Frequency
Percent
Row Pct
Col Pct

N

Y

Total

C

3
25.00
50.00
42.86

3
25.00
50.00
60.00

6
50.00

E

4
33.33
66.67
57.14

2
16.67
33.33
40.00

6
66.67

Total

7
58.33

5
4 1.67

12
100.00

Key:
C - control
E - experimental
N
no retch and/or vomit
Y - retch and/or vomit
-
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Table 2
Difference in Retching and/or Vomiting by Age
(P>.05)

Frequency
Percent
Row Pct
Col Pct

N

Y
0
0
0
0

4
33.33
100.00
80. 00

4
33.33

7
58.33
87. 50
100. 00

1
8.33
12. 50
20.00

80
66. 67

7
58.33

5
4 1. 67

12
100. 00

40 and Over

Less than 40

Total

Key:
Age:
N

Y

-

-

Total

40 and over
less than 40
no retch and/or vomit
retch and/or vomit

CHAPTER 5
Discussion

The overall incidence of retching and/or vomiting in this study
was 50 percent in the control group and 33 percent in the experimental
group.

While it has been noted that the sample size prevents

statistical significance, possible trends may exist that are similar
to previous studies (2,6,7).

The age of the subject and its effect on

postoperative retching and vomiting proved statistically significant on
the . 05 level.

This correlated with Janhunen and Tammisto which found

females age 40-49 years had the highest incidence of vomiting ( 15).
Most variables in this study were controlled.

The sex, weight,

age, type of operation, duration, type of anesthetic, and preoperative
medication were all controlled.

However, subjective evaluation was

required as to the emotional status of the patient preoperatively as
well as quality of induction by the anesthetist.

The very nature of

subjective evaluation requires comment as to possible limitations on
this study.

Recommendations
The following recommendations for future research are suggested:
1.

Repeat study with an increased sample size to determine
if results would be statistically significant.

2.

Repeat study with an increased sample utilizing only
40-49 year age group to determine if prophylactic
treatment would be statistically significant.
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3.

Repeat study with increased sample size to determine
effect of postoperative administration of narcotics on
patients treated with droperidol.

Conclusion
While the results of this study have not been statistically
significant, a trend of decreased retching and vomiting exists in
those su bjects who received droperidol.

Therefore, droperidol can

not be recommended as routine prophylaxis for the adult female
presenting for total a bdominal hysterectomy.
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Appendix A

Consent Form
The purpose of this study is to determine the effectiveness of a
prescribed dosage of Droperidol in preventing postoperative retching and
vomiting.
Nonpregnant patients, like yourself, under going abdominal surgery
are at an increased risk of suffering from retching and vomiting after
the operation.

It is known that Droperidol (an anti-nausea drug) can

reduce the occurance of retching and vomiting in the postoperative
period.

Droperidol has been used for this purpose since 1963.

Should you decide to participate in this study you will be randomly
assigned to one of two groups:
Group I - Will receive a routine preoperative medication.
Group I I - Will receive a routine preoperative medication plus
a routine dose of Droperidol during the operation.
Upon arrival to the operating room a routine intravenous infusion will
be started.

Your heart beat and blood pressure will be monitored and

anesthesia administered.
The side of effects of Droperidol may include:

mild to moderate

hypotension (low blood pressure) and postoperative drowsiness.
The conduct of anesthesia will be the same regardless of whether or
not you participate in this study.

If at any time during anesthesia

your safety is compromised, the study will be discontinued.
I agree that the information obtained from this study may be used
for teaching or for publication in scientific literature. My name and

27
identity will be kept confidential.
I understand that in the event of any physical and/or mental injury
resulting from my participation in this study, Virginia Commonwealth
University will not offer compensation or medical treatment.

signature

witness

date
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Appendix B

Data Collection Sheet
Patient Data
SubJ'ect #
A SA_ ______
�
Procedure.

Age
Wt

_____

-----

:���_-_-_-_-_-_-_

______
__
____ __
__
_
__ __
__

Pre-op:

satisfactory / unsatisfactory

Induction Time:
Problems:

------

_
____________ __
____________
__ __
__
__

Length of Anesthesia:

hours

______

Recovery Room
Required narcotics:
Pro blems:

__
__
__
____________________ ____
____ ____
__
__
__
_

------

F R EQUENCY
TIME

COMME NTS:

R E TCH ING

VOM IT ING

Appendix C
Raw Data

Weight in
Kilograms

Duration of
Anesthesia

Postop Pain and
Tx Morphine mg.

Retch and/or
Vomit Frequency

Subject
Number

Experimental/
Control

Age in
Years

1

C

38

76.4

2.5

0

1

2

C

44

76

3.2

4

3

3

excluded
from study

19

58

2.6

6

0

Length Time
after Anesthesia

14.0
1.05

4

C

36

56

2.8

0

0

5

C

35

68

2.9

4

0

6

E

34

60

3.1

0

0

7

E

28

50

2.8

0

0

8

E

46

49

3.1

2

1

6.65

9

E

41

55

3.4

0

1

7.76

10

E

38

60

2.8

0

0

11

C

31

62

2.9

4

0

12

E

36

50

2.7

0

0

13

C

45

72

3.0

4

1

2.75

N
'"
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